TRIL - トリリウム・セラピュ―ティクス (Trillium Therapeutics Inc.) トリリウム・セラピュ―ティクス

 TRILのチャート


 TRILの企業情報

symbol TRIL
会社名 Trillium Therapeutics Inc (トリリウム・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種    医療関連(Health Care)
概要 事業概要 --   トリリウム・セラピュ―ティクスは、カナダの持株会社。がん免疫治療法の開発を手掛ける。腫瘍細胞が宿主免疫システムを回避するために利用する免疫調節経路を対象とした前臨床プログラムを実施。同社のプログラムは、悪性腫瘍による分子の上方制御およびヒトモノクロナ―ル抗体をブロックする抗体様融合蛋白が含まれる。   Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-621 and TTI-622, target CD47, a “don’t eat me” signal that cancer cells frequently use to evade the immune system.
本社所在地 2488 Dunwin Drive Mississauga Ontario L5L 1J9 CAN
代表者氏名
代表者役職名
電話番号
設立年月日 38047
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 59人
url www.trilliumtherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/tril
adr_tso
EBITDA EBITDA ー
終値(lastsale) 4.31
時価総額(marketcap) 62169586.38
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 TRILのテクニカル分析


 TRILのニュース

   Pfizer Acquires Biologics Company To Expand Its Oncology Pipeline  2021/09/01 16:02:54 JD Supra
Last week, Pfizer announced that it will acquire Trillium Therapeutics, a clinical stage immune-oncology company based in Cambridge, Massachusetts. Under the agreement, Pfizer reported that it “will acquire all outstanding shares of Trillium not already owned by Pfizer for an implied equity value of $2.26 billion, or $18.50 per share, in cash,” and its two lead molecules. … By: Goodwin
   Forget Trillium Therapeutics Stock (TSX:TRIL): Buy These Pharma Stocks Instead!  2021/08/31 14:41:35 The Motley Fool Canada
Motley Fool investors who want in on a pharma rebound should definitely look into these stocks over Trillium Therapeutics stock (TSX:TRIL)(NASDAQ:TRIL). The post Forget Trillium Therapeutics Stock (TSX:TRIL): Buy These Pharma Stocks Instead! appeared first on The Motley Fool Canada .
   SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Trillium Therapeutics, Inc. Buyout  2021/08/24 16:15:00 Intrado Digital Media
WILMINGTON, Del., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating Trillium Therapeutics, Inc. (Trillium) (NASDAQ CM: TRIL ) regarding possible breaches of fiduciary duties and other violations of law related to Trilliums agreement to be acquired by Pfizer, Inc. Under the terms of the agreement, Trilliums shareholders will receive $18.50 in cash for each share of Trillium common stock they own.
   TRILLIUM ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of TRIL and Encourages Investors to Contact the Firm  2021/08/24 14:50:00 Intrado Digital Media
NEW YORK, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Trillium Therapeutics Inc. (NASDAQ: TRIL) breached their fiduciary duties or violated the federal securities laws in connection with the companys sale to Pfizer Inc. (NYSE: PFE).
   Wall Street Rebounds, Trillium Therapeutics Inc soared 188.8% on Pfizer $2.26Bn Deal  2021/08/24 05:19:30 The Trading Room
Wall Street rallied on Monday, and the Nasdaq reached an all-time closing high as sentiment was boosted by full FDA approval of a COVID-19 vaccine and market participants looked ahead to the Jackson Hole Symposium expected to convene later this week. All three major U.S. stock indexes ended the session sharply higher, with the S&P 500 in the sessions final minutes just failing to hold what would have been a record-high close on wall street
   Trillium Therapeutics' CD47 Assets Show Continued Anti-Tumor Activity In Hematologic Malignancies  2021/04/28 13:11:22 Benzinga
Trillium Therapeutics Inc (NASDAQ: TRIL ) has provided a data update for TTI-622 and 621 programs in hematologic malignancies. As of cut-off data April 12, TTI-622 monotherapy shows a 33% objective response rate (ORR) in relapsed/refractory (R/R) lymphomas at 0.8-18 mg/kg doses, including three new responses (1 Complete Response (CR) + 2 Partial Responses (PRs)) since last data disclosure at the American Society of Hematology 2020 … Full story available on Benzinga.com
   Thinking about buying stock in IsoRay, Trillium Therapeutics, Plug Power, Baudax Bio, or Aslan Pharmaceuticals?  2021/03/17 13:31:00 PR Newswire
NEW YORK, March 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ISR, TRIL, PLUG, BXRX, and ASLN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Trillium Therapeutics Factors Likely to Have Influenced Earnings Results Stock market Insights & financial analysis  2021/03/16 03:19:00 Stock Market Daily
Trillium Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Trillium Therapeutics Inc. (NASDAQ:TRIL) Insider Penka Petrova Sells 5,312 Shares  2021/03/13 14:20:44 Watchlist News
Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) insider Penka Petrova sold 5,312 shares of the firm’s stock in a transaction dated Wednesday, March 10th. The shares were sold at an average price of $11.08, for a total value of $58,856.96. Following the completion of the transaction, the insider now owns 2,708 shares in the company, valued at […]
   Warren Buffett: His Advice on Market Crashes  2021/03/04 19:45:58 The Motley Fool Canada
Warren Buffett generously shares his insights to guide investors prepare for a market crash. He also has a bright outlook for the healthcare sector. In the TSX, Trillium Therapeutics stock is poised to deliver superior gains with two lead drug candidates. The post Warren Buffett: His Advice on Market Crashes appeared first on The Motley Fool Canada .
   Trillium Therapeutics' CD47 Assets Show Continued Anti-Tumor Activity In Hematologic Malignancies  2021/04/28 13:11:22 Benzinga
Trillium Therapeutics Inc (NASDAQ: TRIL ) has provided a data update for TTI-622 and 621 programs in hematologic malignancies. As of cut-off data April 12, TTI-622 monotherapy shows a 33% objective response rate (ORR) in relapsed/refractory (R/R) lymphomas at 0.8-18 mg/kg doses, including three new responses (1 Complete Response (CR) + 2 Partial Responses (PRs)) since last data disclosure at the American Society of Hematology 2020 … Full story available on Benzinga.com
   Thinking about buying stock in IsoRay, Trillium Therapeutics, Plug Power, Baudax Bio, or Aslan Pharmaceuticals?  2021/03/17 13:31:00 PR Newswire
NEW YORK, March 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ISR, TRIL, PLUG, BXRX, and ASLN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Trillium Therapeutics Factors Likely to Have Influenced Earnings Results Stock market Insights & financial analysis  2021/03/16 03:19:00 Stock Market Daily
Trillium Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Trillium Therapeutics Inc. (NASDAQ:TRIL) Insider Penka Petrova Sells 5,312 Shares  2021/03/13 14:20:44 Watchlist News
Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) insider Penka Petrova sold 5,312 shares of the firm’s stock in a transaction dated Wednesday, March 10th. The shares were sold at an average price of $11.08, for a total value of $58,856.96. Following the completion of the transaction, the insider now owns 2,708 shares in the company, valued at […]
   Warren Buffett: His Advice on Market Crashes  2021/03/04 19:45:58 The Motley Fool Canada
Warren Buffett generously shares his insights to guide investors prepare for a market crash. He also has a bright outlook for the healthcare sector. In the TSX, Trillium Therapeutics stock is poised to deliver superior gains with two lead drug candidates. The post Warren Buffett: His Advice on Market Crashes appeared first on The Motley Fool Canada .

 関連キーワード  (― 米国株 トリリウム・セラピュ―ティクス TRIL Trillium Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)